We are independent & ad-supported. We may earn a commission for purchases made through our links.
Advertiser Disclosure
Our website is an independent, advertising-supported platform. We provide our content free of charge to our readers, and to keep it that way, we rely on revenue generated through advertisements and affiliate partnerships. This means that when you click on certain links on our site and make a purchase, we may earn a commission. Learn more.
How We Make Money
We sustain our operations through affiliate commissions and advertising. If you click on an affiliate link and make a purchase, we may receive a commission from the merchant at no additional cost to you. We also display advertisements on our website, which help generate revenue to support our work and keep our content free for readers. Our editorial team operates independently of our advertising and affiliate partnerships to ensure that our content remains unbiased and focused on providing you with the best information and recommendations based on thorough research and honest evaluations. To remain transparent, we’ve provided a list of our current affiliate partners here.

What is Lumefantrine?

By M. C. Hughes
Updated Mar 03, 2024
Our promise to you
The Health Board is dedicated to creating trustworthy, high-quality content that always prioritizes transparency, integrity, and inclusivity above all else. Our ensure that our content creation and review process includes rigorous fact-checking, evidence-based, and continual updates to ensure accuracy and reliability.

Our Promise to you

Founded in 2002, our company has been a trusted resource for readers seeking informative and engaging content. Our dedication to quality remains unwavering—and will never change. We follow a strict editorial policy, ensuring that our content is authored by highly qualified professionals and edited by subject matter experts. This guarantees that everything we publish is objective, accurate, and trustworthy.

Over the years, we've refined our approach to cover a wide range of topics, providing readers with reliable and practical advice to enhance their knowledge and skills. That's why millions of readers turn to us each year. Join us in celebrating the joy of learning, guided by standards you can trust.

Editorial Standards

At The Health Board, we are committed to creating content that you can trust. Our editorial process is designed to ensure that every piece of content we publish is accurate, reliable, and informative.

Our team of experienced writers and editors follows a strict set of guidelines to ensure the highest quality content. We conduct thorough research, fact-check all information, and rely on credible sources to back up our claims. Our content is reviewed by subject-matter experts to ensure accuracy and clarity.

We believe in transparency and maintain editorial independence from our advertisers. Our team does not receive direct compensation from advertisers, allowing us to create unbiased content that prioritizes your interests.

Lumefantrine is an antimalarial drug which means that it fights the parasites that cause malaria. Also known as benflumetol, it is a synthetic compound derived from the organic hydrocarbon fluorene. The drug is never used on its own; instead, it is always paired with a derivative of another antimalarial drug known as artemisinin. As a combination therapy, lumefantrine and artemisinin have been shown to be highly effective against the mild or moderate cases of malaria they are used to treat.

Lumefantrine was developed by a team of Chinese scientists led by Professor Zhou Yiqing at the Institute of Microbiology and Epidemiology in Beijing. It was first used in 1987 in China. The combination therapy perhaps most associated with lumefantrine is marketed by Novartis Pharmaceuticals as Coartem®.

Malaria is spread by mosquito bites which allow parasites from the Plasmodium family to enter the blood stream and travel to the liver. The parasite stays in the liver for a period of time ranging from ten days to a few months or even, occasionally, years. It then begins to reproduce and attack red blood cells. The symptoms of malaria can be severe, even leading to coma and death. Like artemisinin, lumefantrine attacks and destroys the malaria parasites when they are active in the blood cells.

The discovery of lumefantrine and its beneficial properties as part of artemisinin-based combination therapy (ACT) can best be seen in regions where strains of malaria have become resistant to older therapies. In particular, the drug combination has been important for taking the place of traditional therapies based on chloroquine or quinine. ACT therapies are believed to have saved many thousands of lives in the countries that are hardest hit by malaria, including those in sub-Saharan Africa and Southeast Asia.

Nevertheless, lumefantrine therapy can be hard on patients. The course of treatment calls for patients to take one dose of the ACT per day for two days followed by two doses per day for four days. The therapy can cause extreme nausea, muscle weakness, fatigue, and other symptoms — it can even, ironically, cause symptoms also associated with malaria. Nevertheless, patients with mild to moderate malaria who take the drug generally begin to see improvement within days, and studies have reported cure rates in the 95% to 99% range.

The Health Board is dedicated to providing accurate and trustworthy information. We carefully select reputable sources and employ a rigorous fact-checking process to maintain the highest standards. To learn more about our commitment to accuracy, read our editorial process.
Discussion Comments
The Health Board, in your inbox

Our latest articles, guides, and more, delivered daily.

The Health Board, in your inbox

Our latest articles, guides, and more, delivered daily.